| P2093 | author name string | Don Morris | |
| | Amelia Kellar | |
| | Cay Egan | |
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| | Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer | Q24610167 |
| | Lung cancer signatures in plasma based on proteome profiling of mouse tumor models | Q24628852 |
| | BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 |
| | A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 |
| | LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer | Q27026346 |
| | Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma | Q27851448 |
| | Cancer statistics, 2013 | Q27860762 |
| | Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais | Q28213995 |
| | Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 |
| | Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship | Q28278682 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes | Q28343950 |
| | Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase | Q29307795 |
| | ras oncogenes in human cancer: a review | Q29547769 |
| | Lung cancer | Q29615473 |
| | Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 |
| | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 |
| | LKB1 modulates lung cancer differentiation and metastasis | Q30080027 |
| | Mutational activation of c-raf-1 and definition of the minimal transforming sequence | Q30406579 |
| | A mouse model for EML4-ALK-positive lung cancer | Q30485093 |
| | Towards a lung adenocarcinoma proteome map: studies with SP-C/c-raf transgenic mice | Q33243095 |
| | Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer | Q33387620 |
| | Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). | Q33498277 |
| | Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane | Q33666026 |
| | Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer | Q33788519 |
| | Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. | Q51555780 |
| | Conditional gene expression in the respiratory epithelium of the mouse. | Q51725452 |
| | Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. | Q51776233 |
| | Conditional expression of fibroblast growth factor-7 in the developing and mature lung. | Q52169169 |
| | Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung | Q52829676 |
| | DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. | Q53336523 |
| | Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. | Q53420491 |
| | Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. | Q53623316 |
| | Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. | Q54334588 |
| | The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. | Q54632436 |
| | Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. | Q55091443 |
| | Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma | Q59566032 |
| | Expression of SV40 T antigen under control of rabbit uteroglobin promoter in transgenic mice | Q67944833 |
| | Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice | Q69204775 |
| | In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue | Q69919083 |
| | Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse | Q70868054 |
| | Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice | Q71803596 |
| | Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance | Q72427599 |
| | Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes | Q72896685 |
| | Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts | Q72966611 |
| | Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice | Q73038129 |
| | Clonal genetic alterations in the lungs of current and former smokers | Q73443322 |
| | Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts | Q73605051 |
| | Effect of navelbine on inhibition of tumor growth, cellular differentiation and estrogen receptor status on Lewis lung carcinoma | Q73676384 |
| | Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein | Q73698300 |
| | Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice | Q74181043 |
| | Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models | Q74469123 |
| | Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study | Q74784116 |
| | Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model | Q79106481 |
| | Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor | Q79856185 |
| | Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel | Q82064003 |
| | Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas | Q82297408 |
| | A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens | Q42255354 |
| | Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts | Q42451922 |
| | Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers | Q42508199 |
| | Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene | Q42661743 |
| | H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts | Q42806772 |
| | Crizotinib--latest champion in the cancer wars? | Q42846140 |
| | Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy | Q43152537 |
| | Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer | Q43299264 |
| | Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development | Q43589131 |
| | ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study | Q44323232 |
| | Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. | Q44435203 |
| | Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer | Q44652158 |
| | United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets | Q44772598 |
| | Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy | Q44795389 |
| | A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40 T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter | Q45734452 |
| | Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice | Q45872028 |
| | Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study | Q46068556 |
| | Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors | Q46131765 |
| | Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. | Q46312574 |
| | Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. | Q47745236 |
| | Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors | Q34112230 |
| | Transgenic mouse models for lung cancer. | Q34150005 |
| | New driver mutations in non-small-cell lung cancer | Q34161395 |
| | Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture | Q34318211 |
| | Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 |
| | Abnormal centrosome amplification in the absence of p53. | Q34374717 |
| | Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis | Q34444361 |
| | Insertion of the v-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer | Q34577063 |
| | Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors | Q34666826 |
| | ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time | Q35033300 |
| | Tumor Suppressor Genes in Lung Cancer | Q35113183 |
| | Human lung cancer and p53: the interplay between mutagenesis and selection | Q35413576 |
| | A rapid and scalable system for studying gene function in mice using conditional RNA interference | Q35627849 |
| | The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer | Q35817516 |
| | Mouse bronchiolar cell carcinogenesis. Histologic characterization and expression of Clara cell antigen in lesions induced by N-nitrosobis-(2-chloroethyl) ureas | Q35830432 |
| | Life in the fast lane: mammalian disease models in the genomics era. | Q36135110 |
| | EML4-ALK fusion lung cancer: a rare acquired event | Q36485308 |
| | Definition of the human raf amino-terminal regulatory region by deletion mutagenesis | Q36766229 |
| | Etoposide in the management of non-small cell lung cancer | Q37155339 |
| | Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model | Q37412014 |
| | Progress and applications of mouse models for human lung cancer | Q37685745 |
| | Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer | Q38075218 |
| | Morphometric analysis of CC10-hASH1 transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma | Q38303978 |
| | KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 |
| | Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells | Q39111275 |
| | Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo | Q39843658 |
| | Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors | Q39888381 |
| | Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. | Q39893186 |
| | Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? | Q39973091 |
| | mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft | Q40181537 |
| | p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment | Q40212070 |
| | Conjugated linoleic acid reduced metastasized LL2 tumors in mouse peritoneum | Q40245759 |
| | Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma | Q40275475 |
| | Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras | Q40424687 |
| | Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. | Q40458801 |
| | Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xeno | Q40527533 |
| | SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer | Q40647641 |
| | Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor | Q40965905 |
| | Homozygous deletions of human chromosome 3p in lung tumors. | Q41119371 |
| | Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma | Q42017054 |
| | Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes | Q42053053 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung neoplasm | Q15124212 |
| | lung cancer | Q47912 |
| | animal disease model | Q64732998 |
| | murine model | Q122890741 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 621324 | |
| P577 | publication date | 2015-01-01 | |
| | 2015-05-03 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Preclinical Murine Models for Lung Cancer: Clinical Trial Applications | |
| P478 | volume | 2015 | |